1. "2019"
Formats
  1. Journal Article (2145)
  2. Meeting Abstract (2088)
  3. Review (529)
  4. Editorial (275)
  5. Book Section (252)
  6. Guidelines (108)
  7. Correspondence (89)
  8. Research Letter (47)
  9. Conference Paper (44)
  10. Miscellaneous (25)
  11. Book Whole (10)
Groups
  1. Department of Medicine (2451)
  2. Solid Tumor Oncology Division (1409)
  3. GSK Faculty (1204)
  4. Sloan Kettering Institute Postdocs (1163)
  5. Surgery (938)
  6. Hematologic Malignancies, Division of (923)

More Groups

People
  1. Sergio Giralt (97)
  2. Marc Ladanyi (96)
  3. Maria Arcila (84)
  4. Miguel-Angel Perales (82)
  5. Alexander Drilon (76)
  6. David Hyman (74)

More People

Years
  1. 2019 (5612)
Publications
  1. Journal of Clinical Oncology (457)
  2. Blood (268)
  3. Cancer Research (192)
  4. Annals of Oncology (163)
  5. International Journal of Radiation Oncology, Biology, Physics (124)
  6. Modern Pathology (112)

More Publications

Publishers
  1. Elsevier Inc. (696)
  2. American Society of Clinical Oncology (518)
  3. Springer (445)
  4. American Association for Cancer Research (343)
  5. Nature Publishing Group (337)
  6. Oxford University Press (325)

More Publishers

Results (5612)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Association of body mass index (BMI) with clinical outcomes in 203 metastatic clear cell renal cell carcinoma (ccRCC) patients (pts) treated with immuno-oncology (IO) agents
    Meeting Abstract

    Ged, Y.; Lee, C. H.; Sanchez, A.; Duzgol, C.; Chaim, J.; Carlo, M. I.; Foster, A.; Akin, O.; Feldman, D. R.; Hakimi, A. A.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Systemic therapy for advanced clear cell renal cell carcinoma (ccRCC) after progression on immune-oncology plus VEGF targeted therapy combinations (IO-VEGF)
    Meeting Abstract

    Ged, Y.; Gupta, R.; Duzgol, C.; Shapnik, N.; Redzematovic, A.; Kotecha, R.; Voss, M. H.; Feldman, D. R.; Akin, O.; Patil, S.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Long term morbidity and mortality among survivors of infant neuroblastoma: A report from the Childhood Cancer Survivor Study (CCSS)
    Meeting Abstract

    Friedman, D. N.; Goodman, P. J.; Leisenring, W.; Diller, L.; Cohn, S. L.; Tonorezos, E. S.; Howell, R. M.; Smith, S. A.; Wolden, S. L.; Nathan, P. C.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Efficacy of maintenance olaparib for newly diagnosed, advanced ovarian cancer patients (pts) by BRCA1 or BRCA2 mutation in the phase III SOLO1 trial
    Meeting Abstract

    Friedlander, M.; Moore, K. N.; Colombo, N.; Scambia, G.; Kim, B. G.; Oaknin, A.; Lisyanskaya, A. S.; Floquet, A.; Leary, A.; Sonke, G. S.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Patient-reported outcomes (PROs) in NRG oncology/NSABP B-39/RTOG 0413: A randomized phase III study of conventional whole breast irradiation (WBI) versus partial breast irradiation (PBI) in stage 0, I, or II breast cancer
    Meeting Abstract

    Ganz, P. A.; Cecchini, R. S.; White, J. R.; Vicini, F.; Julian, T. B.; Arthur, D. W.; Rabinovitch, R.; Kuske, R. R.; Parda, D. S.; Scheier, M.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • A pilot safety study of gemcitabine and cisplatin (GC) with atezolizumab (A) as first-line therapy in patients (pts) with metastatic urothelial cancer (mUC)
    Meeting Abstract

    Funt, S. A.; Jatwani, K.; Makris, M.; Regazzi, A. M.; Lee, C. H.; Teo, M. Y.; McHugh, D. J.; McCoy, A. S.; Hettich, G.; Wong, P.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Frameshift mutations (Fsindel) complement tumor mutation burden (TMB) in predicting survival after immune checkpoint inhibitors (ICI) in a pancancer analysis
    Meeting Abstract

    Florou, V.; Park, W.; Hosein, P. J.; Wilky, B. A.; Trent, J. C.; Lopes, G.
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Decreasing postoperative opioid prescriptions in ambulatory extended recovery patients
    Meeting Abstract

    Fearon, N.; Chesnut, G. T.; Benfante, N.; Assel, M.; Mauzoul, S.; Levine, M.; Broach, V.; Vickers, A.; Eastham, J. A.; Twersky, R.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Factors associated with one-year mortality after debulking surgery in older women with ovarian cancer
    Meeting Abstract

    Filippova, O. T.; Tew, W. P.; O'Cearbhaill, R. E.; Sonoda, Y.; Long-Roche, K. C.; Zivanovic, O.; Gardner, G. J.; Chi, D.; Shahrokni, A.
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • ACCURACY: Phase (P) 2 trial of AL101, a pan-Notch inhibitor, in patients (pts) with recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC) with Notch activating mutations (Notch(act mut))
    Meeting Abstract

    Ferrarotto, R.; Ho, A. L.; Wirth, L. J.; Dekel, E.; Walker, R. W.; Vergara-Silva, A. L.
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save